Drugs / Elismetrep
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03471130 | Apr → Oct 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03381404 | Dec 2017 → Jan 2018 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02803268 | Jun 2016 → Jan 2017 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02675309 | Feb → Mar 2016 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02536209 | Aug → Nov 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02429102 | Apr → Nov 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06848075 | Mar → Aug 2025 | migraine disorder | Kallyope Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05123196 | Nov 2021 → Nov 2022 | diabetic polyneuropathy | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03541200 | Apr 2018 → Nov 2019 | — | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03291067 | Oct 2017 → Oct 2018 | premature menopause | Tanabe Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03172598 | Jul 2017 → Aug 2018 | diabetic polyneuropathy | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07674654 | Jul 2026 → Jun 2028 expected | migraine disorder | Kallyope Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07645924 | Jul 2026 → Feb 2027 expected | migraine disorder | Kallyope Inc. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elismetrep | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07674654 ↗ |
| Known as | K-304 | “Elismetrep (K-304) Dose Level 1” NCT06848075 ↗1“Elismetrep (K-304)” NCT07645924 ↗ |
| Known as | MT 8554 | “This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula...” NCT03471130 ↗ |
| Action | Inhibit | “Transient receptor potential cation channel subfamily M member 8 inhibitor” CHEMBL3682589 ↗ |
| Modality | Small molecule | — CHEMBL3682589 ↗ |
| Route | Oral | “MT-8554 1mg QD, oral, 12 weeks” NCT03291067 ↗ |
| Target | TRPM8 | “Transient receptor potential cation channel subfamily M member 8 inhibitor” CHEMBL3682589 ↗ |